Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Oxford BioMedica plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Oxford BioMedica plc - Product Pipeline Review - 2014', provides an overview of the Oxford BioMedica plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Oxford BioMedica plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Oxford BioMedica plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Oxford BioMedica plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Oxford BioMedica plc's pipeline products Reasons to buy - Evaluate Oxford BioMedica plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Oxford BioMedica plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Oxford BioMedica plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Oxford BioMedica plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oxford BioMedica plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Oxford BioMedica plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Oxford BioMedica plc Snapshot 5 Oxford BioMedica plc Overview 5 Key Information 5 Key Facts 5 Oxford BioMedica plc - Research and Development Overview 6 Key Therapeutic Areas 6 Oxford BioMedica plc - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Oxford BioMedica plc - Pipeline Products Glance 15 Oxford BioMedica plc - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Oxford BioMedica plc - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Oxford BioMedica plc - Drug Profiles 18 TroVax 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ProSavin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RetinoStat 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 EncorStat 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 EndoAngio-GT 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Glaucoma-GT 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 MoNuDin 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 OXB-102 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Oxford BioMedica plc - Pipeline Analysis 29 Oxford BioMedica plc - Pipeline Products by Target 29 Oxford BioMedica plc - Pipeline Products by Route of Administration 30 Oxford BioMedica plc - Pipeline Products by Molecule Type 31 Oxford BioMedica plc - Pipeline Products by Mechanism of Action 32 Oxford BioMedica plc - Recent Pipeline Updates 33 Oxford BioMedica plc - Dormant Projects 39 Oxford BioMedica plc - Company Statement 40 Oxford BioMedica plc - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Oxford BioMedica plc, Key Information 5 Oxford BioMedica plc, Key Facts 5 Oxford BioMedica plc - Pipeline by Indication, 2014 8 Oxford BioMedica plc - Pipeline by Stage of Development, 2014 9 Oxford BioMedica plc - Monotherapy Products in Pipeline, 2014 10 Oxford BioMedica plc - Partnered Products in Pipeline, 2014 11 Oxford BioMedica plc - Partnered Products/ Combination Treatment Modalities, 2014 12 Oxford BioMedica plc - Out-Licensed Products in Pipeline, 2014 13 Oxford BioMedica plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Oxford BioMedica plc - Phase II, 2014 15 Oxford BioMedica plc - Phase I, 2014 16 Oxford BioMedica plc - Preclinical, 2014 17 Oxford BioMedica plc - Pipeline by Target, 2014 29 Oxford BioMedica plc - Pipeline by Route of Administration, 2014 30 Oxford BioMedica plc - Pipeline by Molecule Type, 2014 31 Oxford BioMedica plc - Pipeline Products by Mechanism of Action, 2014 32 Oxford BioMedica plc - Recent Pipeline Updates, 2014 33 Oxford BioMedica plc - Dormant Developmental Projects,2014 39 Oxford BioMedica plc, Subsidiaries 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.